These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18779351)

  • 1. Effect of protein binding on the pharmacological activity of highly bound antibiotics.
    Schmidt S; Röck K; Sahre M; Burkhardt O; Brunner M; Lobmeyer MT; Derendorf H
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3994-4000. PubMed ID: 18779351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein binding and antimicrobial activity of ceftriaxone: comparative assessments by gradient plate technique and time-kill study.
    Li RC; Yung L; Cheng NC
    J Chemother; 2004 Dec; 16(6):524-9. PubMed ID: 15700842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug-Plasma Protein Binding Interactions.
    Baker MA; Schneider EK; X Huang J; Cooper MA; Li J; Velkov T
    ACS Chem Biol; 2016 Dec; 11(12):3353-3364. PubMed ID: 27682196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
    Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model.
    Dhanani JA; Ahern B; Lupinsky L; Jackson K; Wallis SC; Abdul-Aziz MH; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
    Hilliard NJ; Johnson CN; Armstrong SH; Quarles S; Waites KB
    Int J Antimicrob Agents; 2002 Aug; 20(2):136-40. PubMed ID: 12297363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of plasma protein binding on antimicrobial activity using time-killing curves.
    Zeitlinger MA; Sauermann R; Traunmüller F; Georgopoulos A; Müller M; Joukhadar C
    J Antimicrob Chemother; 2004 Nov; 54(5):876-80. PubMed ID: 15472003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model.
    Xuan D; Banevicius M; Capitano B; Kim MK; Nightingale C; Nicolau D
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2990-5. PubMed ID: 12183258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.
    Cottagnoud P; Pfister M; Cottagnoud M; Acosta F; Täuber MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1943-7. PubMed ID: 12760871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.
    Kussmann M; Schuster L; Wrenger S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M
    Perit Dial Int; 2016 11-12; 36(6):662-668. PubMed ID: 27680756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin.
    Gulian JM; Dalmasso C; Gonard V
    Chemotherapy; 1990; 36(2):91-7. PubMed ID: 2311445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae.
    Sevillano D; Giménez MJ; Alou L; Aguilar L; Cafini F; Torrico M; González N; Echeverría O; Coronel P; Prieto J
    J Antimicrob Chemother; 2007 Jul; 60(1):156-8. PubMed ID: 17483149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
    J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
    Gómez-Garcés JL; Alós JI; Alhambra A; Hernáiz C
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):67-70. PubMed ID: 15743576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
    Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
    J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unbound fraction of ertapenem in intensive care unit patients.
    Liebchen U; Kratzer A; Wicha SG; Kees F; Kloft C; Kees MG
    J Antimicrob Chemother; 2014 Nov; 69(11):3108-11. PubMed ID: 24962030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.